Gene Abnormality
17
7
8
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (17)
Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Spermatogonial Differentiation Via Testicular Organoid
Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age
iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray
INDIcators for Clarifying the bAckground of exTreme Obesity in childRen
Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma
Study on Susceptibility Genes of Anterior Cruciate Ligament, Patella Dislocation and Discoid Meniscus
Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer
Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer
Genetic Profile in Patients With Aortic Syndrome
Correlation of Genetic Susceptibility Genes to Inflammatory Bowel Disease in Chinese Han Population
Endometrial Heparin-binding Epidermal Growth Factor Expression
B2 Adrenergic Receptor Gene Polymorphism in Bronchial Asthma
Genotyping of Non-small Cell Lung Cancer